April 24, 2014

As part of the launch of DSN’s new microsite, DrugStoreNews.com/Pain-Management, DSN had the opportunity to speak with Carmen Catizone, executive director of the National Association of Boards of Pharmacy, regarding a new initiative that the association is spearheading to address the current patient access problem when it comes to pain management pharmaceuticals.

January 8, 2014

News stories about doctor shopping and prescription pad pilfering in pursuit of a pain-pill induced high have become commonplace, prompting many legislators and regulators to consider further restrictions on pain medicines like hydrocodone compounds. But there may be a story that’s not being told — that the patients who suffer from chronic pain and need that hydrocodone to reclaim their lives are being stigmatized. The prevalence of pain pill abuse has left in its wake as many as 116 million legitimate pain sufferers who are finding it more difficult to access their therapies.

January 2, 2014

One reason pain patient advocates are so passionate about what they do is because they are pain patients themselves — they know the stigma associated with chronic pain; they know how difficult it can be to access appropriate pain therapy sometimes. That’s the story of Gina Libby, volunteer pain patient advocate who has lived with chronic pain for more than 20 years.

July 23, 2015

A new coalition has formed to ensure safe access to over-the-counter pain relief remedies. The Protecting Access to Pain Relief Coalition officially launched on June 22 to help ensure that American consumers continue to have access to, and choice of, safe and effective pain relief, including acetaminophen.

May 6, 2015

The Consumer Pain Advocacy Task Force recently requested the Department of Health and Human Services to begin the budget process for its National Pain Strategy to speed implementation. 

April 21, 2015

Industry associations on Tuesday praised a House vote to pass Rep. Tom Marino's drug diversion bill.

March 31, 2015

The drug is Food and Drug Administration-approved to treat opioid-induced constipation in adults with chronic, non-cancer pain. 

March 13, 2015

An Alliance for Aging Research survey found that consumers want to maintain nonprescription access to acetaminophen. 

January 26, 2015

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.

January 14, 2015

Egalet Corp. last week announced the licensing and acquisition of two pain products. Egalet has agreed to license worldwide rights to Oxaydo (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting from Acura Pharmaceuticals, the company stated.

January 14, 2015

The University of Florida's Pharm.D. program recently released an infographic around the risks associated with acetaminophen use. 

January 9, 2015

NeuroMetrix is making a splash at this year's International Consumer Electronics Show with its launch of Quell, an OTC chronic pain relieving device.

December 9, 2014

From 2009 to 2013, the number of Americans using prescription opiates declined 9.2%, yet both the number of opioid prescriptions filled and the number of days of medication per prescription rose more than 8% in that time period. 

November 20, 2014

Purdue Pharma on Thursday announced that the Food and Drug Administration approved Hysingla ER (hydrocodone bitartrate) extended‐release tablets CII, a once‐daily, single‐entity medication formulated using Purdue’s proprietary extended‐release solid oral platform, Resistec.

November 18, 2014

Chattem on Tuesday announced that IcyHot SmartRelief, a drug-free, over-the-counter pain management system, is now available nationwide.

October 22, 2014

Pfizer last week announced that the Food and Drug Administration approved a revised label for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII, to include abuse-deterrence studies. 

 

October 15, 2014

The resurgence of iconic pain relief brands Tylenol and Excedrin continue to contribute to the slight growth across internal analgesic tablets. It’s a $3.2 billion book of business across U.S. multi-outlets, according to IRI, that is up slightly by 0.8% for the 52 weeks ended Aug. 10. 

August 25, 2014

Pharmaceutical company Iroko announced today that a new version its anti-inflammatory drug Zorvolex had been approved by the Food and Drug Administration.

August 20, 2014

Wahl is differentiating itself from other products on the shelf through a new approach that combines a massager with hot-cold gel packs, helping to increase circulation and reduce swelling.

August 20, 2014

The lion’s share of the analgesics business may be in internal analgesics — sales of which totaled $3.6 billion, up 1.1% for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI — but it’s alternative pain relievers that may represent the growth opportunity.

August 20, 2014

Who is the alternative analgesic pain consumer? “The majority of these people [in search of external pain relief] have chronic pain and are already taking prescriptions and using multiple methods of pain relief,” said Jenny McLaughlin, product manager for Walh Therapeutic Massagers. “Our research shows people are coming into the health-and-wellness area once a month.”

August 20, 2014

The entire external analgesic category is up 6.7%, reaching a base of $486.9 million across total U.S. multi-outlets for the 52 weeks ended June 15, according to IRI data. And Salonpas, with a 10.9% dollar share, is helping to drive that growth with positive sales gains of 28.7% to $52.9 million.

August 13, 2014

The Arthritis Society has partnered with McKesson Canada's four retail banners Guardian, I.D.A., PROXIM and the Medicine Shoppe Canada pharmacies to launch an exclusive pain management program to support Canadians living with arthritis directly in their communities.

 

July 8, 2014

NeuroMetrix on Tuesday announced that its wearable technology for treatment of chronic pain received 510(k) clearance from the Food and Drug Administration for over-the-counter use.